Displacement, cervical intervertebral disc without myelopathy

GUIDELINE TITLE
Displacement, cervical intervertebral disc without myelopathy. In: The medical disability advisor: workplace for guidelines for disability duration, sixth edition.

BIBLIOGRAPHIC SOURCE(S)
Displacement, cervical intervertebral disc without myelopathy. In: The medical disability advisor: workplace for guidelines for disability duration. 6th ed. Westminster (CO): Reed Group; 2009. p. 9. [7 references]

GUIDELINE STATUS
This is the current release of the guideline.

It updates a previous version: Reed Group. Displacement, cervical intervertebral disc without myelopathy. Westminster (CO): Reed Group; 2005. 9 p. [6 references]

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

December 16, 2008 - Antiepileptic drugs: The U.S. Food and Drug Administration (FDA) has completed its analysis of reports of suicidality (suicidal behavior or ideation [thoughts]) from placebo-controlled clinical trials of drugs used to treat epilepsy, psychiatric disorders, and other conditions. Based on the outcome of this review, FDA is requiring that all manufacturers of drugs in this class include a Warning in their labeling and develop a Medication Guide to be provided to patients prescribed these drugs to inform them of the risks of suicidal thoughts or actions. FDA expects that the increased risk of suicidality is shared by all antiepileptic drugs and anticipates that the class labeling change will be applied broadly.

abrir aquí para acceder al documento AHRQ NGC completo:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=14581&nbr=&string=